DOCSLIB.ORG

Pregabalin for Fibromyalgia: Some Relief but No Cure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pregabalin for Fibromyalgia: Some Relief but No Cure CURRENT DRUG THERAPY LAUREN KIM, MD SARAH LIPTON, MD ATUL DEODHAR, MD Assistant Professor of Medicine, Oregon Chief Resident in Medicine, Oregon Associate Professor of Medicine, Division Health & Science University, Portland, OR Health & Science University, Portland, OR of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR Pregabalin for fibromyalgia: Some relief but no cure ■■ ABSTRACT regabalin (Lyrica) is a novel analogue of P the neurotransmitter gamma aminobutyr- What is the role of pregabalin (Lyrica) in the treatment ic acid (GABA) with analgesic, anticonvul- of fibromyalgia? In this article the authors explore the sant, and anxiolytic activity. Its approval by putative pathophysiology of fibromyalgia, pregabalin’s the US Food and Drug Administration (FDA) mechanism of action and evidence of efficacy, and its in 2007 for the treatment of fibromyalgia made emerging role in treating this challenging disease. it the first drug approved for this indication. Until then, management of fibromyalgia en- ■■ KEY POINTS tailed drugs to treat pain, sleep, fatigue, and psychological disorders, and a strong emphasis Several lines of evidence point to functional abnormali- on exercise and physical therapy. ties in the central nervous system as being responsible Those who still question the validity of fi- for fibromyalgia. bromyalgia as a diagnosis object to drug com- panies “benefiting” from the sale of such drugs.1 But many hail pregabalin as an important ad- Clinical trials found pregabalin superior to placebo. Nev- vance in our understanding of the pathogenesis ertheless, patients need to have reasonable expectations of fibromyalgia and how to treat it. A key ques- of its possible benefit. tion remains: How will pregabalin fit into the treatment of this often-challenging disease? In most patients with fibromyalgia, a multidisciplinary approach is used to treat pain, sleep disturbance, and ■ FROM FIBROSITIS TO FIBROMYALGIA fatigue, along with comorbidities such as neurally medi- ated hypotension and psychiatric disorders. Fibromyalgia is a syndrome characterized by widespread pain. Chronic muscular pain is a Research with pregabalin enhances our understanding common problem, but fibromyalgia is distin- of fibromyalgia and may point the way to future treat- guished from other pain disorders by additional ments. findings, such as consistent areas of tenderness (tender points), nonrestorative sleep, severe fatigue, and frequent psychological comorbidi- ties such as depression and anxiety. Fibromyalgia was originally termed “fibro- sitis” in 1904 by Sir William Gowers, who de- scribed it as a painful condition of the fibrous tissue, which he believed was due to inflamma- tion in the muscles.2,3 For several decades, re- search was dedicated to looking for pathology in the muscle tissue, which was thought to be the major source of pain for most patients with doi:10.3949/ccjm.76a.08024 fibromyalgia. CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 76 • NUMBER 4 APRIL 2009 255 Downloaded from www.ccjm.org on October 5, 2021. For personal use only. All other uses require permission. PREGABALIN FOR FIBROMYALGIA In the mid-1970s, Dr. H. Moldofsky, a While much of the evidence for central noted sleep researcher, reported on abnor- sensitization in fibromyalgia is from animal malities of the alpha-delta component of non- studies, the phenomenon has also been stud- rapid-eye-movement sleep in these patients. ied in humans. Desmeules et al8 found that, He subsequently collaborated with Dr. Hugh compared with people without fibromyalgia, A. Smythe, who helped define the fibromyal- those with fibromyalgia had significantly low- gia tender points. Fibrositis was subsequently er thresholds of pain as assessed subjectively renamed fibromyalgia syndrome, since it was and measured objectively using the nocicep- agreed that there was no true inflammation in tive flexion R-III reflex, which the authors de- muscles or fibrous tissue. scribed as “a specific physiologic correlate for In 1990, the American College of Rheu- the objective evaluation of central nocicep- matology published “classification criteria” for tive pathways.” the disease.4 The criteria include two main Wind-up. Prolonged stimulation of C fibers features: in the dorsal horn can result in the phenom- • A history of widespread pain (“widespread” enon of wind-up, which refers to the temporal being defined as in the axial distribution, summation of second pain. in both the left and right sides of the body, A painful stimulus evokes two pain sig- and above and below the waist), which nals. The first signal is brief and travels must be present for 3 months or more, and rapidly to the spinal cord via myelinated • Tenderness in at least 11 of 18 specified fibers (A fibers). The second signal, which points that is elicited when a pressure of is related to chronic pain and is described as 4 kg (the amount of pressure required to dull, aching, or burning, travels more slowly blanch a thumbnail) is applied in steady to the dorsal horn via unmyelinated fibers increments starting at 1 kg. (C fibers), the synapses of which use the Although pain is subjective and therefore dif- neurotransmitter glutamate. Temporal sum- ficult to assess, the classification criteria did make mation is a phenomenon observed in exper- it easier to study the disease in a uniform way and iments in which a series of painful stimuli Pain is led to an explosion of research in this field. are applied at regular intervals of about 2 subjective seconds; although each stimulus is identi- ■ FUNCtioNAL ABNORMALitiES cal in intensity, subjects perceive them as and therefore IN THE CENTRAL NERVOUS SYSTEM increasing in intensity. The reason: during difficult this repetitive stimulation, N-methyl-d- to assess Research to date points to the pain in fibromy- aspartate (NMDA) receptors become acti- algia as being mediated by changes in the cen- vated, leading to the removal of a magne- tral nervous system rather than in the muscu- sium block within the receptor. This results loskeletal system, as was initially thought. in an influx of calcium into the neuron and In the dorsal horn of the spinal cord, noci- activation of protein kinase C, nitric oxide ceptive (pain-sensing) neurons from the pe- synthase, and cyclooxygenase. Ultimately, riphery synapse with the second-order neu- the firing rates of the nociceptive neurons rons that carry the pain signal to the brain. In are increased and the peripheral pain signal fibromyalgia, several processes seem to amplify is strongly amplified.6 the signal. Wind-up has been shown to lead to char- Central sensitization is defined as en- acteristics of central sensitization related to hanced excitability of neurons in the dorsal C-fiber activity in animals.7 Staud et al9 stud- horn. Its features include augmented sponta- ied wind-up in patients with and without neous neuronal activity, enlarged receptive fibromyalgia using series of repetitive thermal field areas, and enhanced responses generated stimulation to produce temporal summation. by large- and small-caliber primary afferent fi- Though wind-up was evoked in both groups, bers. It can result from prolonged or strong ac- differences were observed both in the magni- tivity in the dorsal horn neurons, and it leads tude of sensory response to the first stimulus to the spread of hyperactivity across multiple within a series and in the amount of temporal spinal segments.5–7 summation within a series. 256 CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 76 • NUMBER 4 APRIL 2009 Downloaded from www.ccjm.org on October 5, 2021. For personal use only. All other uses require permission. KIM AND COLLEAGUES Elevated excitatory neurotransmitters. ■ PREGABALIN In 1994, Russell et al10 showed that the con- centration of substance P, an excitatory neu- Pregabalin is an alpha-2-delta ligand similar to rotransmitter, was three times higher in the GABA, but it does not act on GABA recep- cerebrospinal fluid of people with fibromyalgia tors. Rather, it binds with high affinity to the than in normal controls. alpha-2-delta subunit of voltage-gated presyn- Harris and colleagues11 reported that glu- aptic calcium channels, resulting in reduction tamate, another excitatory neurotransmitter, of calcium flow through the channels, which is elevated within the brain in people with fi- subsequently inhibits the release of neurotrans- bromyalgia. They further showed that the lev- mitters including glutamate, norepinephrine, els of glutamate within the insula of the brain and substance P.15–17 Animal studies suggest are directly associated with the levels of both that the decrease in the levels of these excit- experimental pressure-evoked pain thresholds atory neurotransmitters is the mechanism of and clinical pain ratings in fibromyalgia pa- action of pregabalin, resulting in its analgesic, tients. anticonvulsant, and anxiolytic benefit.15 An- Evidence from imaging studies. Other other potential mechanism of pregabalin is en- objective evidence of central sensitization in hancement of slow-wave sleep, demonstrated fibromyalgia patients comes from studies using in one study in healthy human subjects.18 novel imaging. Besides fibromyalgia, pregabalin is also ap- Gracely et al12 performed functional mag- proved for the treatment of diabetic peripheral netic resonance imaging (MRI) in people with neuropathy, postherpetic neuralgia, general- and without fibromyalgia while applying pres- ized anxiety disorder, and social anxiety disor- sure to their thumbs with
Load more

Recommended publications
  • Pregabalin Is First Drug Approved for Fibromyalgia
    50 Pain Medicine C LINICAL P SYCHIATRY N EWS • August 2007 Pregabalin Is First Drug Approved for Fibromyalgia BY ELIZABETH MECHCATIE that are not usually painful, and that pre- cording to the revised prescribing infor- The daily dose should be administered Senior Writer gabalin may reduce the degree of pain ex- mation for pregabalin. The two studies— in two divided doses per day, starting at a perienced by patients with fibromyalgia by a 14-week double-blind placebo-controlled total daily dose of 150 mg/day, which regabalin has become the first drug binding to a specific protein within study and a 6-month randomized with- may be increased to 300 mg/day, within 1 to win approval by the Food and “overexcited nerve cells.” drawal study—found that treatment was week; the maximum dose is 450 mg/day, PDrug Administration for the man- The approval “marks an important ad- associated with a reduction in pain by vi- according to the prescribing information. agement of fibromyalgia. vance, and provides a reason for optimism sual analog scale and improvements based The most common side effects in the tri- The FDA based the approval on two for the many patients on a patient global as- als were mild to moderate dizziness and double-blind, controlled trials of approxi- who will receive pain Side effects such as sessment and on the sleepiness, blurred vision, weight gain, dry mately 1,800 patients. Data from the stud- relief ” with prega- Fibromyalgia Impact mouth, and swelling of the hands and feet ies have shown that patients with fi- balin, Dr.
    [Show full text]
  • Intravenous Ketamine Alleviates Pain in a Rheumatoid Arthritis Patient with Comorbid Fibromyalgia
    Case Report J Med Cases. 2018;9(5):142-144 Intravenous Ketamine Alleviates Pain in a Rheumatoid Arthritis Patient With Comorbid Fibromyalgia Ashraf F. Hannaa, b, Bishoy Abrahama, Andrew Hannaa, Micheal McKennaa, Adam J. Smitha Abstract bance, and psychological distress [4]. It is commonly regarded as the “prototypical central sensitivity syndrome” [5]. While A 49-year-old woman with rheumatoid arthritis (RA) and comorbid its etiology is not fully understood, fibromyalgia is thought to fibromyalgia presented to the clinic in extreme pain, described to be result from abnormal central pain processing and increased a 10 on an 11-point pain intensity numerical rating scale (PI-NRS). central sensitivity that results in intense, widespread pain. Fi- Because the patient also met the diagnostic criteria for fibromyalgia bromyalgia is diagnosed using the 2010 American College of and conventional medications did not achieve adequate pain control Rheumatology (ACR) criteria [6]: 1) Widespread pain index for either condition, the off-label use of intravenous (IV) ketamine (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5 or WPI was presented as an alternative therapeutic option. The patient un- 3 - 6 and SS scale score ≥ 9. 2) Symptoms have been present derwent 10 consecutive IV infusion sessions with increasing doses at a similar level for at least 3 months. 3) The patient does not of ketamine hydrochloride without any complications. Following the have a disorder that would otherwise explain the pain. 10th infusion, the patient reported that her pain was virtually non- A recent epidemiological study characterized the preva- existent (PI-NRS 0 - 1). lence of fibromyalgia among patients without pain, with re- gional pain, and with widespread pain [4].
    [Show full text]
  • Ketamine for Chronic Non- Cancer Pain: a Review of Clinical Effectiveness, Cost- Effectiveness, And
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Ketamine for Chronic Non- Cancer Pain: A Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: May 28, 2020 Report Length: 28 Pages Authors: Khai Tran, Suzanne McCormack Cite As: Ketamine for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: CADTH; 2020 May. (CADTH rapid response report: summary with critical appraisal) ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • Pubmed/19078481?Dopt=Abstract
    Efficacy of tramadol in treatment of pain in fibromyalgia. - Pu... https://www.ncbi.nlm.nih.gov/pubmed/19078481?dopt=Abstract PubMed Format: Abstract J Clin Rheumatol. 2000 Oct;6(5):250-7. Efficacy of tramadol in treatment of pain in fibromyalgia. Russell IJ1, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Author information Abstract An outpatient, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy and safety of tramadol in the treatment of the pain of fibromyalgia syndrome. One hundred patients with fibromyalgia syndrome, (1990 American College of Rheumatology criteria), were enrolled into an open-label phase and treated with tramadol 50-400 mg/day. Patients who tolerated tramadol and perceived benefit were randomized to treatment with tramadol or placebo in the double-blind phase. The primary efficacy outcome measurement was the time (days) to exit from the double-blind phase because of inadequate pain relief, which was reported as the cumulative probability of discontinuing treatment because of inadequate pain relief. One hundred patients entered the open-label phase; 69% tolerated and achieved benefit with tramadol. These patients were then randomized to continue tramadol (n = 35) or convert to a placebo (n = 34) during a 6-week, double-blind treatment period. The Kaplan-Meier estimate of cumulative probability of discontinuing the double blind period because of inadequate pain relief was significantly lower in the tramadol group compared with the placebo group (p = 0.001). Twenty (57.1%) patients in the tramadol group successfully completed the entire double-blind phase compared with nine (27%) in the placebo group (p = .015).
    [Show full text]
  • Therapeutic Class Overview Neuropathic Pain and Fibromyalgia Agents
    Therapeutic Class Overview Neuropathic Pain and Fibromyalgia Agents INTRODUCTION • Neuropathic pain is commonly described by patients as burning or electrical in nature and results from injury or damage to the nervous system (Herndon et al 2017). Management of neuropathic pain may prove challenging due to unpredictable patient response to drug therapy (Attal et al 2010). • Fibromyalgia is characterized by chronic musculoskeletal pain with unknown etiology and pathophysiology. Patients typically complain of widespread musculoskeletal pain, fatigue, cognitive disturbance, psychiatric symptoms, and multiple somatic symptoms (Goldenberg 2019). Fibromyalgia is often difficult to treat and requires a multidisciplinary, individualized treatment program (Goldenberg 2018). • This review focuses on medications that are approved by the Food and Drug Administration (FDA) for the treatment of fibromyalgia, neuropathic pain, and/or post-herpetic neuralgia (PHN). The products in this review include Cymbalta (duloxetine), Gralise (gabapentin ER), Horizant (gabapentin enacarbil ER), Lidoderm (lidocaine 5% patch), Lyrica (pregabalin), Lyrica CR (pregabalin ER), Neurontin (gabapentin), Nucynta ER (tapentadol ER), Qutenza (capsaicin), Savella (milnacipran), and ZTlido (lidocaine 1.8% topical system). These agents represent a variety of pharmacologic classes, including anticonvulsants, serotonin-norepinephrine reuptake inhibitors (SNRIs), extended-release (ER) opioids, and topical analgesics. As such, these agents hold additional FDA-approved indications
    [Show full text]
  • Corporate Medical Policy Nerve Fiber Density Testing AHS – M2112 “Notification”
    Corporate Medical Policy Nerve Fiber Density Testing AHS – M2112 “Notification” File Name: nerve_fiber_density_testing Origination: 01/01/2019 Last CAP Review: n/a Next CAP Review: 01/01/2020 Last Review: 01/01/2019 Policy Effective April 1, 2019 Description of Procedure or Service Nerve fiber density testing involves analysis of skin biopsy stained with an antibody to antiprotein gene product 9.5 (Wilkinson et al., 1989) which avidly stains all axons (Dalsgaard, Rydh, & Haegerstrand, 1989). The number and morphology of axons within the epidermis are evaluated to determine epidermal nerve fiber density (McCarthy et al., 1995) and assess for the presence and degree of neuropathy (A. G. Smith & Gibson, 2018). ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for nerve fiber density testing when it is determined to be medically necessary because the medical criteria and guidelines shown below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. When nerve fiber density testing is covered Skin biopsy with epidermal nerve fiber density measurement for the diagnosis of small-fiber neuropathy
    [Show full text]
  • Fibromyalgia
    Fibromyalgia SANGITA CHAKRABARTY, MD, MSPH, Meharry Medical College, Nashville, Tennessee ROGER ZOOROB, MD, MPH, Meharry Medical College and Vanderbilt University, Nashville, Tennessee Fibromyalgia is an idiopathic, chronic, nonarticular pain syndrome with generalized tender points. It is a multisystem disease characterized by sleep disturbance, fatigue, headache, morning stiffness, paresthesias, and anxiety. Nearly 2 percent of the general population in the United States suffers from fibromyalgia, with females of middle age being at increased risk. The diagnosis is primarily based on the presence of widespread pain for a period of at least three months and the presence of 11 tender points among 18 specific anatomic sites. There are certain comorbid con- ditions that overlap with, and also may be confused with, fibromyalgia. Recently there has been improved recognition and understanding of fibromyalgia. Although there are no guidelines for treatment, there is evidence that a multidimensional approach with patient education, cognitive behavior therapy, exercise, physical therapy, and pharmacologic therapy can be effective. (Am Fam Physician 2007;76:247-54. Copyright © 2007 American Academy of Family Physicians.) This article exemplifies ibromyalgia is an idiopathic, chronic, gesting the contribution of both genetic and the AAFP 2007 Annual nonarticular pain syndrome defined environmental factors.4 Clinical Focus on manage- ment of chronic illness. by widespread musculoskeletal Demographic and social characteristics ▲ pain and generalized tender points associated with the presence of fibromyalgia See editorial on F(Table 1). Other common symptoms include are female sex, being divorced, failing to com- page 290. ▲ sleep disturbances, fatigue, headache, morning plete high school, and low income. Psycho- Patient information: Handouts on fibromyalgia stiffness, paresthesias, and anxiety.
    [Show full text]
  • The Journal of Rheumatology Volume 75, No. Is Fibromyalgia a Neuropathic Pain Syndrome?
    The Journal of Rheumatology Volume 75, no. Is fibromyalgia a neuropathic pain syndrome? Michael C Rowbotham J Rheumatol 2005;75;38-40 http://www.jrheum.org/content/75/38 1. Sign up for TOCs and other alerts http://www.jrheum.org/alerts 2. Information on Subscriptions http://jrheum.com/faq 3. Information on permissions/orders of reprints http://jrheum.com/reprints_permissions The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields. Downloaded from www.jrheum.org on September 24, 2021 - Published by The Journal of Rheumatology Is Fibromyalgia a Neuropathic Pain Syndrome? MICHAEL C. ROWBOTHAM ABSTRACT. The fibromyalgia syndrome (FM) seems an unlikely candidate for classification as a neuropathic pain. The disorder is diagnosed based on a compatible history and the presence of multiple areas of musculoskeletal tenderness. A consistent pathology in either the peripheral or central nervous system (CNS) has not been demonstrated in patients with FM, and they are not at higher risk for diseases of the CNS such as multiple sclerosis or of the peripheral nervous system such as peripheral neuropathy. A large proportion of FM suf- ferers have accompanying symptoms and signs of uncertain etiology, such as chronic fatigue, sleep distur- bance, and bowel/bladder irritability. With the exception of migraine headaches and possibly irritable bowel syndrome, the accompanying disorders are clearly not neurological in origin. The impetus to classify the FM as a neuropathic pain comes from multiple lines of research suggesting widespread pain and tenderness are associated with chronic sensitization of the CNS.
    [Show full text]
  • Fibromyalgia
    The Voice of the Patient A series of reports from the U.S. Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development Initiative Fibromyalgia Public Meeting: March 26, 2014 Report Date: October 2014 Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA) Table of Contents Introduction ......................................................................................................................................3 Meeting overview ..................................................................................................................................... 3 Report overview and key themes ............................................................................................................. 4 Topic 1: Disease Symptoms and Daily Impacts That Matter Most to Patients .......................................5 Perspectives on most significant symptoms ............................................................................................. 6 Overall impact of fibromyalgia on daily life .............................................................................................. 8 Topic 2: Patient Perspectives on Treatments for Fibromyalgia .............................................................9 Prescriptions and over-the-counter drugs ................................................................................................ 9 Non-drug therapies ................................................................................................................................
    [Show full text]
  • Amitriptyline Information Booklet
    Drug information Amitriptyline AMITRIPTYLINE is used to relieve pain in several long-term conditions including arthritis, back pain and fibromyalgia Amitriptyline information booklet Introduction • arthritis (arth-rye-tus) • back pain Amitriptyline (a-muh-trip-tuh-leen) is a drug that can reduce your • fibromyalgia (fie-bruh-my-al-juh) pain and discomfort, and help you get a good night’s sleep. • tension headaches and migraines You can discuss the benefits and risks of taking amitriptyline with • damage to nerve endings in limbs, which may be described to healthcare professionals before you start treatment, so you’re able you as peripheral neuropathy (pe-rif-er-ul new-ro-pa-thee). to make an informed decision. You may not be able to take amitriptyline if: What is amitriptyline and how is it used? • you’ve had an allergic reaction to a medication in the past • you have heart problems, as it can make them worse Amitriptyline is a type of drug called a tricyclic antidepressant. • you have uncontrolled bipolar disorder These drugs were originally developed to treat anxiety and depression, but when taken at a low dose they can reduce or • you have the rare inherent blood disorder porphyria stop pain. (por-fear-ee-ya) which affects the nervous system • you have liver or kidney problems Amitriptyline works by increasing the amount of serotonin your • you have epilepsy, as it can increase the risk of seizures brain makes. Serotonin is a chemical, called a neurotransmitter, that • you’ve had or are having treatment for depression, as some the brain sends out to nerves in the body.
    [Show full text]
  • Milnacipran, a Serotonin and Norepinephrine Reuptake Inhibitor: a Novel Treatment for Fibromyalgia
    Drug Evaluation Milnacipran, a serotonin and norepinephrine reuptake inhibitor: a novel treatment for fibromyalgia Milnacipran hydrochloride is a serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor that was recently approved by the US FDA for the treatment of fibromyalgia (FM). Evidence has accumulated suggesting that, in animal models, milnacipran may exert pain-mitigating influences involving norepinephrine- and serotonin-related processes at supraspinal, spinal and peripheral levels in pain transmission. Milnacipran has demonstrated efficacy for the reduction of pain as well as improvements in global assessments of well-being and functional capacity among treated FM patients. Its role in addressing comorbidities associated with FM, including visceral pain and migraine, has, as yet, to be investigated. Milnacipran may be of special interest for use in patients for whom hepatic dysfunction precludes the use of other agents, for example, duloxetine. It has a negligible influence on cytochrome metabolism, and therefore may be of particular benefit in patients requiring multiple concurrently prescribed medications. Milnacipran may comprise a reasonable option in the armamentarium of treatments available to manage FM. KEYWORDS: antidepressants n chronic pain n fibromyalgian milnacipran n serotonin Raphael J Leo and norepinephrine reuptake inhibitor Department of Psychiatry, School of Medicine and Fibromyalgia (FM) is a syndrome characterized Several pharmacological approaches have Biomedical Sciences, by chronic, widespread musculoskeletal pain and been advocated for the treatment of FM. State University of New York at tenderness. The prevalence of FM in the general Because of their impact on these presump- Buffalo, Erie County Medical population is estimated to be 2–4%; it tends to tive pathophysiologic processes, antidepres- Center, 462 Grider Street, show a female predilection, and increases with sants have frequently been advocated for Buffalo, NY 14215, USA age [1,2].
    [Show full text]
  • Beyond Depression: Other Uses for Tricyclic Antidepressants
    REVIEW Joanne Schneider, DNP, RN, CNP Mary Patterson, CNP Xavier F. Jimenez, MD, MA Center for Comprehensive Pain Recovery, Center for Comprehensive Pain Recovery, Center for Comprehensive Pain Recovery, Neurological Institute, Cleveland Clinic Neurological Institute, Cleveland Clinic Neurological Institute, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH Beyond depression: Other uses for tricyclic antidepressants ABSTRACT ost tricyclic antidepressants (TCAs) M have US Food and Drug Administration Tricyclic antidepressants (TCAs) were originally designed approval for treatment of depression and anxi- and marketed for treating depression, but over time they ety disorders, but they are also a viable off-label have been applied to a variety of conditions, mostly off- option that should be considered by clinicians label. TCAs can serve as first-line or augmenting drugs in specialties beyond psychiatry, especially for for neuropathic pain, headache, migraine, gastrointesti- treating pain syndromes. Given the ongoing nal syndromes, fibromyalgia, pelvic pain, insomnia, and epidemic of opioid use disorder, increasing atten- psychiatric conditions other than depression. This article tion has been drawn to alternative strategies for reviews pharmacology, dosing, and safety considerations chronic pain management, renewing an interest for these uses. in the use of TCAs. This review summarizes the pharmacologic KEY POINTS properties of TCAs, their potential indications Amitriptyline is the most useful TCA for many painful in conditions other than depression, and safety conditions. considerations. ■ BRIEF HISTORY OF TRICYCLICS TCAs can be especially helpful for patients with a pain syndrome or insomnia with comorbid depression, al- TCAs were originally designed in the 1950s and marketed later for treating depression.
    [Show full text]